Novel Swellable/Expandable Gastroretentive Floating Films of Gliclazide Folded in Capsule Shell for the Effective Management of Diabetes Mellitus: Formulation Development, Optimization and In Vitro Evaluation
Authors:
- 1 February 2021
- journal article
- research article
- Published by Bentham Science Publishers Ltd. in Current Drug Therapy
- Vol. 16 (1) , 100-112
Abstract
Background: Gliclazide (GLZ) belongs to the second-generation of sulphonylureas; it is a drug of choice for the management of type II DM. It belongs to BCS Class II. The major site of drug absorption for GLZ is the stomach; it displays variation in the drug absorption rate and bioavailability due to the shorter gastric retention time. The floating mechanism gets affected when the gastric fluid level is not sufficiently higher, which ultimately obstructs the floating behavior, which is the major limitation of reported formulations. This limitation can be overcome by folding the film into the capsule shell dissolved in the gastric fluid and the film swells/expands to dimensions higher than pylorus sphincter (12mm), thus preventing its evacuation. Objective: The study aims to explore the floating mechanism in the design of films along with a tendency to expand by swelling and unfolding by utilizing a mixture of hydrophilic and hydrophobic polymer to achieve the controlled drug delivery and prolonged gastric retention of drug. Methods: The gastroretentive floating films were formulated by the solvent casting technique using 32 full factorial designs and subjected to in vitro evaluation parameters, drug-excipient compatibility, Xray diffraction and accelerated stability study. Results: The pre-formulation study established the purity and identification of a drug. FTIR study confirmed no drug excipient interaction. F3, F6, and F9 were optimized based on in vitro floating characteristics, swelling/expanding ability, and unfolding time. All developed formulations were unfolded within 14-22 min after capsule disintegration. The F3 was selected as the final formulation as its ability to control the release of the drug for 24 hrs followed by zero-order kinetics having super case 2 transport. XRD confirmed the amorphousness of the drug within the formulation. The stability study results revealed that the formulation was quite stable at extreme storage conditions. Conclusion: The developed novel formulation has good potential for the effective management and treatment of diabetes mellitus.Keywords
This publication has 34 references indexed in Scilit:
- Application of Design of Experiment for Floating Drug Delivery of Tapentadol HydrochlorideComputational and Mathematical Methods in Medicine, 2013
- In vitro and in vivo evaluation of gastroretentive floating drug delivery system of ofloxacinAsian Journal of Pharmaceutical Sciences, 2013
- Development of novel gastroretentive drug delivery system of gliclazide: hollow beadsDrug Development and Industrial Pharmacy, 2013
- Design of a gastroretentive mucoadhesive dosage form of furosemide for controlled releaseActa Pharmaceutica Sinica B, 2012
- Bioequivalence Study of Modified-Release Gliclazide Tablets in Healthy VolunteersISRN Pharmacology, 2012
- Type 2 Diabetes Mellitus: A Review of Current TrendsOman Medical Journal, 2012
- Formulation and evaluation of mucoadhesive glipizide filmsActa Pharmaceutica, 2011
- Mucoadhesive buccal films of glibenclamide: Development and evaluationInternational Journal of Pharmaceutical Investigation, 2011
- Dissolution enhancement of gliclazide by preparation of inclusion complexes with β-cyclodextrinAsian Journal of Pharmaceutics, 2008
- Studies on indomethacin inserts prepared by water-soluble polymersIl Farmaco, 2001